Company Overview - RenovoRx is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug delivery platform aimed at improving therapeutic outcomes for cancer patients [4] - The company's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precise therapeutic delivery to directly target tumors while potentially minimizing toxicities compared to systemic intravenous therapy [4] - RenovoRx's lead product candidate, RenovoGem™, is a novel oncology drug-device combination product currently in Phase III clinical development for the treatment of locally advanced pancreatic cancer (LPAC) [4][5] Leadership and Strategy - Ryan Witt has been appointed as Senior Vice President, Head of Corporate Strategy and Partnerships, bringing extensive corporate strategy and operational experience from roles at Spinogenix, Immix Biopharma, StartX, and UCLA Biodesign [1][7][9] - Mr Witt's leadership will focus on advancing RenovoRx's pivotal Phase III clinical trial, expanding development opportunities into additional cancers, and exploring new commercial business development opportunities with the company's therapeutic technology [9] - The appointment highlights RenovoRx's commitment to exploring and executing on clinical and commercial business development opportunities for its RenovoGem™ investigational combination product and other therapeutic agents [5] Technology and Pipeline - RenovoRx's TAMP™ therapy platform offers the potential for increased safety, tolerance, and improved efficacy in targeted cancer treatment [4] - RenovoGem™ is being investigated under a US investigational new drug application regulated by the FDA's 21 CFR 312 pathway for the treatment of LPAC [4] - The company is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care [6] Industry and Partnerships - Mr Witt has a strong track record in leading corporate strategy and managing partnerships across top 25 global biopharma companies [1] - He serves on Biocom's Capital Development Committee, which hosts Partnering Days with large multinational healthcare companies including Baxter, Bristol Myers Squibb, Daiichi-Sankyo, GSK, Novo Nordisk, and Eli Lilly [1] - RenovoRx has collaborated with Imugene and has clinical data delivering gemcitabine with its drug-delivery platform, demonstrating the potential of its technology [4]
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships